Germany / Highest Honours for BioNTech Founders; Bayer’s Growth Predictions; Merck Making Further French Investments
A roundup of some of the most important recent news from German pharma, including state honours for the founders of…
Sanofi Aventis Germany
Last updated: 01.06.2015
Address: Sanofi-Aventis Deutschland GmbH
Industriepark Höchst, K703
65926 Frankfurt
,Germany
Tel: 0180 / 2 222010
Web: http://www.sanofi.de/l/de/de/index.jsp
Company description
The Sanofi-Aventis Deutschland GmbH is the German subsidiary of one of the world’s leading pharmaceutical companies. The Group employs approximately 100,000 employees worldwide and maintains strong market positions in the regions of North America, Europe and Asia. Its core business is the original innovative prescription drugs for the treatment (drugs) and prevention (vaccines) of serious, widespread diseases. The R & D expenditures by sanofi-aventis in 2008 amounted to 4.6 billion euros, of which, the Sanofi-Aventis Deutschland GmbH about 600 million euros worn. But not only the high use of resources is decisive – the research from sanofi-aventis is one of the most productive and successful worldwide. Currently, sanofi-aventis 65 novel drugs and vaccines in development. Of these 27 projects are in advanced clinical stage III or in the admission process. The focus is on seven core therapeutic areas: diabetes / metabolism, cardiovascular, thrombosis, central nervous system, internal medicine, oncology and vaccines. In Germany, one of sanofi-aventis with sales (including export) of 4.0 billion euros of the leading providers of innovative medicines.
Products and services
Related
Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness…
Germany / The Biotech Behind Pfizer’s COVID-19 Vaccine Candidate
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant…
Pharma Faces / Teresa Rodó, Head of Global Healthcare Operations, Merck
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to…
Merck KGaA / Big-Ticket Investments in Manufacturing Scale & Digital Innovation
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
News Roundup / German Pharma: February 2020
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big…
Bayer: Betting Big on Cell & Gene Therapy
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as…
Merck Announces EUR 1 Billion HQ Investment
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up…
Interview with Elmar Schnee , President of Merck Serono and Member of the…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout…
Interview with Andreas Fibig, CEO, Bayer Schering Pharma
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth…
Interview with Ralf Göddertz, General Manager of Germany, Austria and…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with…
